Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Fei JuYong LuoChaolong LinXian JiaZilong XuRui TianYanhua LinMin ZhaoYating ChangXiaoxuan HuangShaopeng LiWenfeng RenYaning QinMengqin YuJizong JiaJinle HanWenxin LuoJun ZhangGuo FuXiangzhong YeChenghao HuangNing-Shao XiaPublished in: Journal for immunotherapy of cancer (2022)
Localized delivery of PD-1 inhibitors by engineered YST-OVH was a highly effective and safe strategy for cancer immunotherapy. YST-OVH also synergized with CTLA-4 or TIM-3 blockade to enhance the immune response to cancer. These data provide a strong rationale for further clinical evaluation of this novel therapeutic approach.